Form 10-Q CANCER GENETICS, INC For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Cancer Genetics (CGIX) Tops Q3 EPS by 5c
November 10, 2016 7:20 AM ESTCancer Genetics (NASDAQ: CGIX) reported Q3 EPS of ($0.23), $0.05 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $6.8 million versus the consensus estimate of $6.93 million.
For earnings history and earnings-related data on Cancer Genetics (CGIX) click here.
... More